Conflict of interest
ONCOLOGY
UG has received research support from BMS and Novartis; speaker honorarium from BMS, Jazz Pharmaceuticals, and Novartis; and consulting fees from BMS. PF has received research support and honoraria from BMS. UP has received research funding from Amgen, BMS, Janssen, Merck, and Novartis; consulting fees from BMS; honoraria from AbbVie, BMS, Geron, Janssen, Novartis, and Takeda. RB has received research funding and honoraria for advisory boards from BMS and Taiho Pharma. VS has served on advisory boards for BMS, Geron, Gilead, Menarini, Novartis, and Takeda; and has served on speaker’s bureau for BMS and Novartis. MD-C reports honoraria, consulting fees, and travel support, and has served on advisory boards for BMS, Novartis, and Takeda. AY, DT, GZ, DM, and CH are employees of BMS, and hold stock ownership. SF and XH are employees of BMS. RZ is an employee of GSK and former employee of BMS. RSK reports consulting fees from AbbVie, Acceleron Pharma, BMS, Geron, Jazz Pharmaceuticals, and Novartis; and speakers bureau or honoraria for AbbVie, BMS, CTI BioPharma, Innovent, Jazz Pharmaceuticals, Novartis, PharmaEssentia, Taiho Oncology, and Takeda. AMZ reports consultancy fees from AbbVie, Acceleron, Agios, Amgen, Aprea, Astellas, BeyondSpring, Boehringer-Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/BMS, Daiichi Sankyo, Epizyme, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme; research funding for AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer-Ingelheim, Cardiff Oncology, BMS, Incyte, Medimmune/Astrazeneca, Novartis, Otsuka, Pfizer, Takeda, and Trovagene; honoraria for AbbVie, Acceleron, Agios, Amgen, Aprea, Astellas, Beyondpspring, Boehringer-Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/BMS, Daiichi Sankyo, Epizyme, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme; clinical trial committees for Abbvie, BMS, Geron, Gilead, Kura, and Novartis; and travel support for Cardiff Oncology, Novartis, and Pfizer. GG-M reports grant or research support from AbbVie, Amphivena, Aprea, BMS, Curis, Forty Seven, H3 Biomedicine, Helsinn, Merck, Novartis, and Onconova; and consultancy fees from Astex, BMS, Genentech, and Helsinn.